In a move aimed at speeding up pharmaceutical research while reducing paperwork, the Union Ministry of Health and Family Welfare has proposed amendments to the Drugs Rules, 1945, that would make it easier to import small quantities of drugs for laboratory examination, testing and analysis. The proposal replaces the existing licensing process for most such imports with an acknowledgement-based online system, a step expected to help researchers, start-ups and pharmaceutical companies begin scientific work more quickly.

Under the proposed amendment, applicants seeking to import limited quantities of medicines or drug substances for analytical and non-clinical testing will only need to submit a prior online intimation. Once an acknowledgement is generated, they can proceed with the import instead of waiting for a formal licence, commonly issued under Form 11.

Analytical testing involves checking a drug's identity, purity and quality, while non-clinical testing refers to laboratory studies conducted before medicines are tested on humans. Scientists often import small quantities of compounds to examine their chemical behaviour, stability, and safety using specialised laboratory instruments before deciding whether further research is warranted.

The simplified procedure will not apply to certain high-risk categories, including sex hormones, cytotoxic medicines used to treat cancer, beta-lactam antibiotics that may trigger severe allergic reactions, biologics containing live microorganisms, and narcotic or psychotropic substances. These medicines will continue to require prior regulatory approval because of their potential risks to public health and misuse.

The proposal builds on amendments made to the New Drugs and Clinical Trials Rules, 2019, in January 2026, when the government introduced a similar notification-based system for domestic test licences. Extending the approach to imported materials is expected to reduce regulatory delays and lower compliance costs for research organisations.

Experts have long argued that excessive administrative procedures can slow early-stage pharmaceutical innovation. The WHO has consistently emphasised that effective regulatory systems should protect public health while ensuring timely access to quality medicines and encouraging scientific development. Likewise, the International Council for Harmonisation promotes risk-based regulatory practices that simplify low-risk research activities without compromising safety.

If notified after stakeholder consultation, the amendment could strengthen India's position as a global pharmaceutical research hub by allowing laboratories and innovators to focus more on science and less on paperwork, while retaining regulatory oversight where public safety demands stricter controls.